1-3 of 3
Brenda Walker, RN
Close
Sort by
Journal Articles

Expanded Access Program Of Ponatinib (AP24534) For Patients (Pts) With Refractory Chronic Myeloid Leukemia (CML) Or Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)

Ghayathri Jeyakumar, MD, Hagop M. Kantarjian, MD, Kendra L. Sweet, MD, Cecilia Y Arana Yi, MD, Nitin Jain, MD, Elias Jabbour, MD, Alfonso Quintas-Cardama, MD, Susan O'Brien, MD, Brenda Walker, RN, Sherry R. Pierce, RN, BS, Tapan M. Kadia, MD, Farhad Ravandi, MD, Javier Pinilla, Jorge E. Cortes, MD
Journal: Blood
Blood (2013) 122 (21): 4044.
https://doi.org/10.1182/blood.V122.21.4044.4044
Published: 2013
Journal Articles

Memory Impairment in Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Patients (pts) Treated with Dasatinib Tyrosine Kinase Inhibitor (TKI) Therapy,

Naveen Pemmaraju, MD, Hagop M. Kantarjian, Maria F Tanaka, Susan O'Brien, MD, Elias Jabbour, Alfonso Quintas-Cardama, MD, Gautam Borthakur, Farhad Ravandi, MD, Srdan Verstovsek, MD, PhD, Elizabeth Burton, Brenda Walker, RN, Jorge E. Cortes
Journal: Blood
Blood (2011) 118 (21): 3771.
https://doi.org/10.1182/blood.V118.21.3771.3771
Published: 2011
Journal Articles

Results of a Phase II Trial of Dasatinib As Frontline Therapy for Chronic Myeloid Leukemia (CML) In Chronic Phase (CP)

Naveen Pemmaraju, MD, Hagop M. Kantarjian, Rajyalakshmi Luthra, PhD, Susan O'Brien, MD, Elias Jabbour, Alfonso Quintas-Cardama, MD, Gautam Borthakur, Farhad Ravandi, MD, Srdan Verstovsek, MD, PhD, Elizabeth Burton, Brenda Walker, RN, Jorge E. Cortes
Journal: Blood
Blood (2011) 118 (21): 1700.
https://doi.org/10.1182/blood.V118.21.1700.1700
Published: 2011